Biomarkers in congestive heart failure

Biomarkers in Cardiovascular Diseases

Volumn , Issue , 2013, Pages 101-145

  Andreoli, Chiara ^a   Parissis, John T ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84941008402     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (235)

1. Adams, J.E., III, D.R. Abendschein, and A.S. Jaffe. 1993a. Biochemical markers of myocardial injur. Is MB creatine kinase the choice for the 1990s? Circulation 88: 750-763.
2. Adams, J.E., III, G.S. Bodor, V.G. Davila-Roman, J.A. Delmez, F.S. Apple, J.H. Ladenson, and A.S. Jaffe. 1993b. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation 88: 101-106.
3. Aggarwal, A., M.D. Esler, F. Socratous, and D.M. Kaye. 2001. Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure. J. Am. Coll. Cardiol. 37: 1246-1251.
4. Altschuld, R.A., R.C. Starling, R.L. Hamlin, G.E. Billman, J. Hensley, L. Castillo, R.H. Fertel, C.M. Hohl, P.M. Robitaille, L.R. Jones et al. 1995. Response of failing canine and human heart cells to beta 2-adrenergic stimulation. Circulation 92: 1612-1618.
5. Anand, I.S., L.D. Fisher, Y.T. Chiang, R. Latini, S. Masson, A.P. Maggioni, R.D. Glazer, G. Tognoni, and J.N. Cohn. 2003. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107: 1278-1283.
6. Anand, I.S., R. Latini, V.G. Florea, M.A. Kuskowski, T. Rector, S. Masson, S. Signorini, P. Mocarelli, A. Hester, R. Glazer, and J.N. Cohn. 2005. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112: 1428-1434.
7. Anand, I.S., T. Kempf, T.S. Rector, H. Tapken, T. Allhoff, F. Jantzen, M. Kuskowski, J.N. Cohn, H. Drexler, and K.C. Wollert. 2010. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 122: 1387-1395.
8. Anker, S.D. and A.J. Coats. 2002. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int. J. Cardiol. 86: 123-130.
9. Anker, S.D., W. Doehner, M. Rauchhaus, R. Sharma, D. Francis, C. Knosalla, C.H. Davos, M. Cicoira, W. Shamim, M. Kemp, R. Segal, K.J. Osterziel, F. Leyva, R. Hetzer, P. Ponikowski, and A.J. Coats. 2003. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107: 1991-1997.
10. Anker, S.D. and S. von Haehling. 2004. Inflammatory mediators in chronic heart failure: an overview. Heart 90: 464-470.
11. Anwaruddin, S., D.M. Lloyd-Jones, A. Baggish, A. Chen, D. Krauser, R. Tung, C. Chae, and J.L. Januzzi, Jr. 2006. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J. Am. Coll. Cardiol. 47: 91-97.
12. Aronson, D. and A.J. Burger. 2003. Neurohumoral activation and ventricular arrhythmias in patients with decompensated congestive heart failure: role of endothelin. Pacing Clin. Electrophysiol. 26: 703-710.
13. Aukrust, P., T. Ueland, F. Muller, A.K. Andreassen, I. Nordoy, H. Aas, J. Kjekshus, S. Simonsen, S.S. Froland, and L. Gullestad. 1998. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 97: 1136-1143.
14. Azevedo, E.R., G.E. Newton, J.S. Floras, and J.D. Parker. 2000. Reducing cardiac filling pressure lowers norepinephrine spillover in patients with chronic heart failure. Circulation 101: 2053-2059.
15. Badgett, R.G., C.D. Mulrow, P.M. Otto, and G. Ramirez. 1996. How well can the chest radiograph diagnose left ventricular dysfunction? J. Gen. Intern. Med. 11: 625-634.
16. Baggiolini, M., B. Dewald, and B. Moser. 1994. Interleukin-8 and related chemotactic cytokines--CXC and CC chemokines. Adv. Immunol. 55: 97-179.
17. Barker, W.H., J.P. Mullooly, and W. Getchell. 2006. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation 113: 799-805.
18. Bedi, M.S., L.A. Postava, S. Murali, G.A. Macgowan, M. Mathier, D.M. McNamara, and B. London. 2004. Interaction of implantable defibrillator therapy with angiotensinconverting enzyme deletion/insertion polymorphism. J. Cardiovasc. Electrophysiol. 15: 1162-1166.
19. Benedict, C.R., D.E. Johnstone, D.H. Weiner, M.G. Bourassa, V. Bittner, R. Kay, P. Kirlin, B. Greenberg, R.M. Kohn, J.M. Nicklas et al. 1994. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J. Am. Coll. Cardiol. 23: 1410-1420.
20. Berger, R., M. Huelsman, K. Strecker, A. Bojic, P. Moser, B. Stanek, and R. Pacher. 2002. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105: 2392-2397.
21. Berger, R., D. Moertl, S. Peter, R. Ahmadi, M. Huelsmann, S. Yamuti, B. Wagner, and R. Pacher. 2010. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J. Am. Coll. Cardiol. 55: 645-653.
22. Berry, C.E. and J.M. Hare. 2004. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J. Physiol. 555: 589-606.
23. Bhargava, V., R. Shabetai, R.A. Mathiasen, N. Dalton, J.J. Hunter, and J. Ross, Jr. 1998. Loss of adrenergic control of the force-frequency relation in heart failure secondary to idiopathic or ischemic cardiomyopathy. Am. J. Cardiol. 81: 1130-1137.
24. Bleumink, G.S., A.M. Knetsch, M.C. Sturkenboom, S.M. Straus, A. Hofman, J.W. Deckers, J.C. Witteman, and B.H. Stricker. 2004. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur. Heart J. 25: 1614-1619.
25. Bonneux, L., J.J. Barendregt, K. Meeter, G.J. Bonsel, and P.J. van der Maas. 1994. Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. Am. J. Public Health 84: 20-28.
26. Bootcov, M.R., A.R. Bauskin, S.M. Valenzuela, A.G. Moore, M. Bansal, X.Y. He, H.P. Zhang, M. Donnellan, S. Mahler, K. Pryor, B.J. Walsh, R.C. Nicholson, W.D. Fairlie, S.B. Por, J.M. Robbins, and S.N. Breit. 1997. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc. Natl. Acad. Sci. USA 94: 11514-11519.
27. Braunwald, E. 2008. Biomarkers in heart failure. N. Engl. J. Med. 358: 2148-2159.
28. Brunner-La Rocca, H.P., D.M. Kaye, R.L. Woods, J. Hastings, and M.D. Esler. 2001. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J. Am. Coll. Cardiol. 37: 1221-1227.
29. Bryant, D., L. Becker, J. Richardson, J. Shelton, F. Franco, R. Peshock, M. Thompson, and B. Giroir. 1998. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 97: 1375-1381.
30. Bursi, F., S.A. Weston, M.M. Redfield, S.J. Jacobsen, S. Pakhomov, V.T. Nkomo, R.A. Meverden, and V.L. Roger. 2006. Systolic and diastolic heart failure in the community. JAMA 296: 2209-2216.
31. Cadnapaphornchai, M.A., A.K. Gurevich, H.D. Weinberger, and R.W. Schrier. 2001. Pathophysiology of sodium and water retention in heart failure. Cardiology 96: 122-131.
32. Carswell, E.A., L.J. Old, R.L. Kassel, S. Green, N. Fiore, and B. Williamson. 1975. An endotoxininduced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72: 3666-3670.
33. Castell, J.V., M.J. Gomez-Lechon, M. David, R. Fabra, R. Trullenque, and P.C. Heinrich. 1990. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 12: 1179-1186.
34. Chidsey, C.A., D.C. Harrison, and E. Braunwald. 1962. Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure. N. Engl. J. Med. 267: 650-654.
35. Chidsey, C.A., E. Braunwald, and A.G. Morrow. 1965. Catecholamine Excretion and Cardiac Stores of Norepinephrine in Congestive Heart Failure. Am. J. Med. 39: 442-451.
36. Choukroun, G., R. Hajjar, J.M. Kyriakis, J.V. Bonventre, A. Rosenzweig, and T. Force. 1998. Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. J. Clin. Invest. 102: 1311-1320.
37. Cicoira, M., A. Rossi, S. Bonapace, L. Zanolla, G. Golia, L. Franceschini, B. Caruso, P.N. Marino, and P. Zardini. 2004. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J. Card. Fail. 10: 403-411.
38. Cohn, J.N., T.B. Levine, M.T. Olivari, V. Garberg, D. Lura, G.S. Francis, A.B. Simon, and T. Rector. 1984. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311: 819-823.
39. Colombo, P.C., J.E. Banchs, S. Celaj, A. Talreja, J. Lachmann, S. Malla, N.B. DuBois, A.W. Ashton, F. Latif, U.P. Jorde, J.A. Ware, and T.H. LeJemtel. 2005. Endothelial cell activation in patients with decompensated heart failure. Circulation 111: 58-62.
40. Communal, C., K. Singh, D.R. Pimentel, and W.S. Colucci. 1998. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 98: 1329-1334.
41. Communal, C., K. Singh, D.B. Sawyer, and W.S. Colucci. 1999. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxinsensitive G protein. Circulation 100: 2210-2212.
42. Cowie, M.R., A. Mosterd, D.A. Wood, J.W. Deckers, P.A. Poole-Wilson, G.C. Sutton, and D.E. Grobbee. 1997. The epidemiology of heart failure. Eur. Heart J. 18: 208-225.
43. Damas, J.K., L. Gullestad, T. Ueland, N.O. Solum, S. Simonsen, S.S. Froland, and P. Aukrust. 2000. CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes. Cardiovasc. Res. 45: 428-436.
44. Damas, J.K., L. Gullestad, H. Aass, S. Simonsen, J.G. Fjeld, L. Wikeby, T. Ueland, H.G. Eiken, S.S. Froland, and P. Aukrust. 2001. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure-modulatory effect of intravenous immunoglobulin. J. Am. Coll. Cardiol. 38: 187-193.
45. Daniels, L.B. and A.S. Maisel. 2007. Natriuretic peptides. J. Am. Coll. Cardiol. 50: 2357-68.
46. Danser, A.H., M.A. Schalekamp, W.A. Bax, A.M. van den Brink, P.R. Saxena, G.A. Riegger, and H. Schunkert. 1995. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 92: 1387-1388.
47. Das, S.R., M.H. Drazner, D.L. Dries, G.L. Vega, H.G. Stanek, S.M. Abdullah, R.M. Canham, A.K. Chung, D. Leonard, F.H. Wians, Jr., and J.A. de Lemos. 2005. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 112: 2163-2168.
48. de Groote, P., J. Dagorn, B. Soudan, N. Lamblin, E. McFadden, and C. Bauters. 2004. B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J. Am. Coll. Cardiol. 43: 1584-1589.
49. Deswal, A., N.J. Petersen, A.M. Feldman, J.B. Young, B.G. White, and D.L. Mann. 2001. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103: 2055-2059.
50. Dharnidharka, V.R., C. Kwon, and G. Stevens. 2002. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am. J. Kidney Dis. 40: 221-226.
51. Ding, Q., T. Mracek, P. Gonzalez-Muniesa, K. Kos, J. Wilding, P. Trayhurn, and C. Bing. 2009. Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology 150: 1688-1696.
52. Ding, S.S., C. Qiu, P. Hess, J.F. Xi, J.P. Clozel, and M. Clozel. 2002. Chronic endothelin receptor blockade prevents renal vasoconstriction and sodium retention in rats with chronic heart failure. Cardiovasc. Res. 53: 963-970.
53. Doehner, W., N. Schoene, M. Rauchhaus, F. Leyva-Leon, D.V. Pavitt, D.A. Reaveley, G. Schuler, A.J. Coats, S.D. Anker, and R. Hambrecht. 2002. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 105: 2619-2624.
54. Doust, J.A., E. Pietrzak, A. Dobson, and P. Glasziou. 2005. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330: 625.
55. Dubois-Rande, J.L., O. Montagne, M. Alvarez-Guerra, C. Nazaret, B. Crozatier, P. Gueret, A. Castaigne, and R.P. Garay. 1996. Endogenous sodium-potassium-chloride cotransport inhibitor in congestive heart failure. J. Am. Coll. Cardiol. 28: 1464-1470.
56. Dzau, V.J., W.S. Colucci, N.K. Hollenberg, and G.H. Williams. 1981. Relation of the reninangiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 63: 645-651.
57. Dzau, V.J. 1987. Renal and circulatory mechanisms in congestive heart failure. Kidney Int. 31: 1402-1415.
58. Elesber, A.A. and M.M. Redfield. 2001. Approach to patients with heart failure and normal ejection fraction. Mayo Clin. Proc. 76: 1047-1052.
59. Elsner, D., A. Muntze, E.P. Kromer, and G.A. Riegger. 1992. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am. J. Cardiol. 70: 494-498.
60. Foley, P.W., B. Stegemann, K. Ng, S. Ramachandran, A. Proudler, M.P. Frenneaux, L.L. Ng, and F. Leyva. 2009. Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. Eur. Heart J. 30: 2749-2757.
61. Folsom, A.R., J.S. Pankow, R.P. Tracy, D.K. Arnett, J.M. Peacock, Y. Hong, L. Djousse, and J.H. Eckfeldt. 2001. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am. J. Cardiol. 88: 112-117.
62. Fonarow, G.C., W.F. Peacock, C.O. Phillips, M.M. Givertz, and M. Lopatin. 2007. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J. Am. Coll. Cardiol. 49: 1943-1950.
63. Francis, G.S., S.R. Goldsmith, T.B. Levine, M.T. Olivari, and J.N. Cohn. 1984. The neurohumoral axis in congestive heart failure. Ann. Intern. Med. 101: 370-377.
64. Gaasch, W.H. 1994. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. JAMA 271: 1276-1280.
65. Gillespie, N.D., G. McNeill, T. Pringle, S. Ogston, A.D. Struthers, and S.D. Pringle. 1997. Cross sectional study of contribution of clinical assessment and simple cardiac investigations to diagnosis of left ventricular systolic dysfunction in patients admitted with acute dyspnoea. BMJ 314: 936-940.
66. Globits, S., H. Frank, B. Pacher, M. Huelsmann, E. Ogris, and R. Pacher. 1998. Atrial natriuretic peptide release is more dependent on atrial filling volume than on filling pressure in chronic congestive heart failure. Am. Heart J. 135: 592-597.
67. Griendling, K.K. and R.W. Alexander. 1997. Oxidative stress and cardiovascular disease. Circulation 96: 3264-3265.
68. Griendling, K.K. and G.A. FitzGerald. 2003. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 108: 1912-1916.
69. Grieve, D.J., and A.M. Shah. 2003. Oxidative stress in heart failure. More than just damage. Eur. Heart J. 24: 2161-2163.
70. Gullestad, L. and P. Aukrust. 2005. Review of trials in chronic heart failure showing broadspectrum anti-inflammatory approaches. Am. J. Cardiol. 95: 17C-23C; discussion 38C-40C.
71. Halliwell B, G.J., ed. Free Radicals in Biology and Medicine. 1989, Oxford University Press: Oxford.
72. Han, W.K., V. Bailly, R. Abichandani, R. Thadhani, and J.V. Bonventre. 2002. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 62: 237-244.
73. Han, W.K., S.S. Waikar, A. Johnson, R.A. Betensky, C.L. Dent, P. Devarajan, and J.V. Bonventre. 2008. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int. 73: 863-869.
74. Hartmann, F., M. Packer, A.J. Coats, M.B. Fowler, H. Krum, P. Mohacsi, J.L. Rouleau, M. Tendera, A. Castaigne, S.D. Anker, I. Amann-Zalan, S. Hoersch, and H.A. Katus. 2004. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 110: 1780-1786.
75. Havranek, E.P., F.A. Masoudi, K.A. Westfall, P. Wolfe, D.L. Ordin, and H.M. Krumholz. 2002. Spectrum of heart failure in older patients: results from the National Heart Failure project. Am. Heart J. 143: 412-417.
76. Heart Failure Society of America 2006. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J. Card. Fail. 12: e1-2.
77. Herget-Rosenthal, S., D. Poppen, J. Husing, G. Marggraf, F. Pietruck, H.G. Jakob, T. Philipp, and A. Kribben. 2004. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin. Chem. 50: 552-558.
78. Herget-Rosenthal, S. 2005. One step forward in the early detection of acute renal failure. Lancet 365: 1205-1206.
79. Heublein, D.M., B.K. Huntley, G. Boerrigter, A. Cataliotti, S.M. Sandberg, M.M. Redfield, and J.C. Burnett, Jr. 2007. Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 49: 1114-1119.
80. Heymes, C., J.K. Bendall, P. Ratajczak, A.C. Cave, J.L. Samuel, G. Hasenfuss, and A.M. Shah. 2003. Increased myocardial NADPH oxidase activity in human heart failure. J. Am. Coll. Cardiol. 41: 2164-2171.
81. Ho, K.K., J.L. Pinsky, W.B. Kannel, and D. Levy. 1993. The epidemiology of heart failure: the Framingham Study. J. Am. Coll. Cardiol. 22: 6A-13A.
82. Hoes, A.W., A. Mosterd, and D.E. Grobbee. 1998. An epidemic of heart failure? Recent evidence from Europe. Eur. Heart J. 19 Suppl L: L2-9.
83. Hokamaki, J., H. Kawano, M. Yoshimura, H. Soejima, S. Miyamoto, I. Kajiwara, S. Kojima, T. Sakamoto, S. Sugiyama, N. Hirai, H. Shimomura, Y. Nagayoshi, K. Tsujita, I. Shioji, S. Sasaki, and H. Ogawa. 2004. Urinary biopyrrins levels are elevated in relation to severity of heart failure. J. Am. Coll. Cardiol. 43: 1880-1885.
84. Horwich, T.B., J. Patel, W.R. MacLellan, and G.C. Fonarow. 2003. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 108: 833-838.
85. Horwich, T.B., M.A. Hamilton, and G.C. Fonarow. 2006. B-type natriuretic peptide levels in obese patients with advanced heart failure. J. Am. Coll. Cardiol. 47: 85-90.
86. Hoste, E.A., G. Clermont, A. Kersten, R. Venkataraman, D.C. Angus, D. De Bacquer, and J.A. Kellum. 2006. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit. Care 10: R73.
87. Hudson, M.P., C.M. O’Connor, W.A. Gattis, G. Tasissa, V. Hasselblad, C.M. Holleman, L.H. Gaulden, F. Sedor, and E.M. Ohman. 2004. Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. Am. Heart J. 147: 546-552.
88. Hulsmann, M., B. Stanek, B. Frey, B. Sturm, D. Putz, T. Kos, R. Berger, W. Woloszczuk, G. Maurer, and R. Pacher. 1998. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J. Am. Coll. Cardiol. 32: 1695-1700.
89. Hunt, S.A., W.T. Abraham, M.H. Chin, A.M. Feldman, G.S. Francis, T.G. Ganiats, M. Jessup, M.A. Konstam, D.M. Mancini, K. Michl, J.A. Oates, P.S. Rahko, M.A. Silver, L.W. Stevenson, and C.W. Yancy. 2009. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119: e391-479.
90. Iwanaga, Y., I. Nishi, S. Furuichi, T. Noguchi, K. Sase, Y. Kihara, Y. Goto, and H. Nonogi. 2006. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J. Am. Coll. Cardiol. 47: 742-748.
91. Jaffe, A.S., V.C. Vasile, M. Milone, A.K. Saenger, K.N. Olson, and F.S. Apple. 2011. Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T. J. Am. Coll. Cardiol. 58: 1819-1824.
92. Januzzi, J.L., R. van Kimmenade, J. Lainchbury, A. Bayes-Genis, J. Ordonez-Llanos, M. Santalo-Bel, Y.M. Pinto, and M. Richards. 2006. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur. Heart J. 27: 330-337.
93. Januzzi, J.L., Jr., C.A. Camargo, S. Anwaruddin, A.L. Baggish, A.A. Chen, D.G. Krauser, R. Tung, R. Cameron, J.T. Nagurney, C.U. Chae, D.M. Lloyd-Jones, D.F. Brown, S. Foran-Melanson, P.M. Sluss, E. Lee-Lewandrowski, and K.B. Lewandrowski. 2005. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol. 95: 948-954.
94. Jhund, P.S., K. Macintyre, C.R. Simpson, J.D. Lewsey, S. Stewart, A. Redpath, J.W. Chalmers, S. Capewell, and J.J. McMurray. 2009. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 119: 515-523.
95. Jourdain, P., G. Jondeau, F. Funck, P. Gueffet, A. Le Helloco, E. Donal, J.F. Aupetit, M.C. Aumont, M. Galinier, J.C. Eicher, A. Cohen-Solal, and Y. Juilliere. 2007. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J. Am. Coll. Cardiol. 49: 1733-1739.
96. Kanani, P.M., C.A. Sinkey, R.L. Browning, M. Allaman, H.R. Knapp, and W.G. Haynes. 1999. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 100: 1161-1168.
97. Kapadia, S.R., K. Yakoob, S. Nader, J.D. Thomas, D.L. Mann, and B.P. Griffin. 2000. Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J. Am. Coll. Cardiol. 36: 208-212.
98. Karlstrom, P., U. Alehagen, K. Boman, and U. Dahlstrom. 2011. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur. J. Heart Fail. 13: 1096-1103.
99. Kaye, D.M., G.W. Lambert, J. Lefkovits, M. Morris, G. Jennings, and M.D. Esler. 1994. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J. Am. Coll. Cardiol. 23: 570-578.
100. Kaye, D.M., J. Lefkovits, G.L. Jennings, P. Bergin, A. Broughton, and M.D. Esler. 1995. Adverse consequences of high sympathetic nervous activity in the failing human heart. J. Am. Coll. Cardiol. 26: 1257-1263.
101. Kaye, D.M., A.M. Dart, G.L. Jennings, and M.D. Esler. 1999. Antiadrenergic effect of chronic amiodarone therapy in human heart failure. J. Am. Coll. Cardiol. 33: 1553-1559.
102. Kempf, T., M. Eden, J. Strelau, M. Naguib, C. Willenbockel, J. Tongers, J. Heineke, D. Kotlarz, J. Xu, J.D. Molkentin, H.W. Niessen, H. Drexler, and K.C. Wollert. 2006. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ. Res. 98: 351-360.
103. Kempf, T., E. Bjorklund, S. Olofsson, B. Lindahl, T. Allhoff, T. Peter, J. Tongers, K.C. Wollert, and L. Wallentin. 2007a. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur. Heart J. 28: 2858-2865.
104. Kempf, T., S. von Haehling, T. Peter, T. Allhoff, M. Cicoira, W. Doehner, P. Ponikowski, G.S. Filippatos, P. Rozentryt, H. Drexler, S.D. Anker, and K.C. Wollert. 2007b. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J. Am. Coll. Cardiol. 50: 1054-1060.
105. King, M.K., M.L. Coker, A. Goldberg, J.H. McElmurray, 3rd, H.R. Gunasinghe, R. Mukherjee, M.R. Zile, T.P. O’Neill, and F.G. Spinale. 2003. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ. Res. 92: 177-185.
106. Kinnunen, P., O. Vuolteenaho, and H. Ruskoaho. 1993. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 132: 1961-1970.
107. Kistorp, C., J. Faber, S. Galatius, F. Gustafsson, J. Frystyk, A. Flyvbjerg, and P. Hildebrandt. 2005. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112: 1756-1762.
108. Kittleson, M.M., M.E. St. John, V. Bead, H.C. Champion, E.K. Kasper, S.D. Russell, I.S. Wittstein, and J.M. Hare. 2007. Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels. Heart 93: 365-367.
109. Knudsen, C.W., T. Omland, P. Clopton, A. Westheim, W.T. Abraham, A.B. Storrow, J. McCord, R.M. Nowak, M.C. Aumont, P. Duc, J.E. Hollander, A.H. Wu, P.A. McCullough, and A.S. Maisel. 2004. Diagnostic value of B-Type natriuretic peptide and chest radiographic findings in patients with acute dyspnea. Am. J. Med. 116: 363-368.
110. Koglin, J., S. Pehlivanli, M. Schwaiblmair, M. Vogeser, P. Cremer, and W. vonScheidt. 2001. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J. Am. Coll. Cardiol. 38: 1934-1941.
111. Kohli, P., M.P. Bonaca, R. Kakkar, A.Y. Kudinova, B.M. Scirica, M.S. Sabatine, S.A. Murphy, E. Braunwald, R.T. Lee, and D.A. Morrow. 2012. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin. Chem. 58: 257-266.
112. Konstam, M.A., M. Gheorghiade, J.C. Burnett, Jr., L. Grinfeld, A.P. Maggioni, K. Swedberg, J.E. Udelson, F. Zannad, T. Cook, J. Ouyang, C. Zimmer, and C. Orlandi. 2007. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297: 1319-1331.
113. Kushner, I. 1982. The phenomenon of the acute phase response. Ann. N.Y. Acad. Sci. 389: 39-48.
114. La Vecchia, L., G. Mezzena, L. Zanolla, M. Paccanaro, L. Varotto, C. Bonanno, and R. Ometto. 2000. Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. J. Heart Lung Transplant 19: 644-652.
115. Lainchbury, J.G., R.W. Troughton, K.M. Strangman, C.M. Frampton, A. Pilbrow, T.G. Yandle, A.K. Hamid, M.G. Nicholls, and A.M. Richards. 2009. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J. Am. Coll. Cardiol. 55: 53-60.
116. Lamblin, N., F. Mouquet, B. Hennache, J. Dagorn, S. Susen, C. Bauters, and P. de Groote. 2005. High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur. Heart J. 26: 2245-2250.
117. LaPointe, M.C. 2005. Molecular regulation of the brain natriuretic peptide gene. Peptides 26: 944-956.
118. Lassus, J., V.P. Harjola, R. Sund, K. Siirila-Waris, J. Melin, K. Peuhkurinen, K. Pulkki, and M.S. Nieminen. 2007. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur. Heart J. 28: 1841-1847.
119. Latini, R., S. Masson, I. Anand, M. Salio, A. Hester, D. Judd, S. Barlera, A.P. Maggioni, G. Tognoni, and J.N. Cohn. 2004. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur. Heart J. 25: 292-299.
120. Latini, R., S. Masson, I.S. Anand, E. Missov, M. Carlson, T. Vago, L. Angelici, S. Barlera, G. Parrinello, A.P. Maggioni, G. Tognoni, and J.N. Cohn. 2007. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 116: 1242-1249.
121. Lee, D.S. and R.S. Vasan. 2005. Novel markers for heart failure diagnosis and prognosis. Curr. Opin. Cardiol. 20: 201-210.
122. Levine, B., J. Kalman, L. Mayer, H.M. Fillit, and M. Packer. 1990. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323: 236-241.
123. Levy, D., S. Kenchaiah, M.G. Larson, E.J. Benjamin, M.J. Kupka, K.K. Ho, J.M. Murabito, and R.S. Vasan. 2002. Long-term trends in the incidence of and survival with heart failure. N. Engl. J. Med. 347: 1397-1402.
124. Li, Y., G. Takemura, K. Kosai, T. Takahashi, H. Okada, S. Miyata, K. Yuge, S. Nagano, M. Esaki, N.C. Khai, K. Goto, A. Mikami, R. Maruyama, S. Minatoguchi, T. Fujiwara, and H. Fujiwara. 2004. Critical roles for the Fas/Fas ligand system in postinfarction ventricular remodeling and heart failure. Circ. Res. 95: 627-636.
125. Lloyd-Jones, D., R.J. Adams, T.M. Brown, M. Carnethon, S. Dai, G. De Simone, T.B. Ferguson, E. Ford, K. Furie, C. Gillespie, A. Go, K. Greenlund, N. Haase, S. Hailpern, P.M. Ho, V. Howard, B. Kissela, S. Kittner, D. Lackland, L. Lisabeth, A. Marelli, M.M. McDermott, J. Meigs, D. Mozaffarian, M. Mussolino, G. Nichol, V.L. Roger, W. Rosamond, R. Sacco, P. Sorlie, T. Thom, S. Wasserthiel-Smoller, N.D. Wong, and J. Wylie-Rosett. 2010. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121: e46-e215.
126. Lloyd-Jones, D.M., M.G. Larson, E.P. Leip, A. Beiser, R.B. D’Agostino, W.B. Kannel, J.M. Murabito, R.S. Vasan, E.J. Benjamin, and D. Levy. 2002. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106: 3068-3072.
127. Logeart, D., G. Thabut, P. Jourdain, C. Chavelas, P. Beyne, F. Beauvais, E. Bouvier, and A.C. Solal. 2004. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J. Am. Coll. Cardiol. 43: 635-641.
128. Logeart, D., J.Y. Tabet, L. Hittinger, G. Thabut, P. Jourdain, P. Maison, J.M. Tartiere, and A.C. Solal. 2008. Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int. J. Cardiol. 127: 228-232.
129. Lopez, B.L., G.L. Liu, T.A. Christopher, and X.L. Ma. 1997. Peroxynitrite, the product of nitric oxide and superoxide, causes myocardial injury in the isolated perfused rat heart. Coron. Artery Dis. 8: 149-153.
130. Lu, Z., X. Xu, X. Hu, S. Lee, J.H. Traverse, G. Zhu, J. Fassett, Y. Tao, P. Zhang, C. dos Remedios, M. Pritzker, J.L. Hall, D.J. Garry, and Y. Chen. 2010. Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation 121: 1474-1483.
131. MacCarthy, P.A., R. Grocott-Mason, B.D. Prendergast, and A.M. Shah. 2000. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. Circulation 101: 142-147.
132. Maeda, K., T. Tsutamoto, A. Wada, N. Mabuchi, M. Hayashi, T. Tsutsui, M. Ohnishi, M. Sawaki, M. Fujii, T. Matsumoto, and M. Kinoshita. 2000. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J. Am. Coll. Cardiol. 36: 1587-1593.
133. Mair, J. 2008. Biochemistry of B-type natriuretic peptide-where are we now? Clin. Chem. Lab Med 46: 1507-1514.
134. Maisel, A., C. Mueller, R. Nowak, W.F. Peacock, J.W. Landsberg, P. Ponikowski, M. Mockel, C. Hogan, A.H. Wu, M. Richards, P. Clopton, G.S. Filippatos, S. Di Somma, I. Anand, L. Ng, L.B. Daniels, S.X. Neath, R. Christenson, M. Potocki, J. McCord, G. Terracciano, D. Kremastinos, O. Hartmann, S. von Haehling, A. Bergmann, N.G. Morgenthaler and S.D. Anker. 2010. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J. Am. Coll. Cardiol. 55: 2062-2076.
135. Maisel, A.S., J. Koon, P. Krishnaswamy, R. Kazenegra, P. Clopton, N. Gardetto, R. Morrisey, A. Garcia, A. Chiu, and A. De Maria. 2001. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am. Heart J. 141: 367-374.
136. Maisel, A.S., P. Krishnaswamy, R.M. Nowak, J. McCord, J.E. Hollander, P. Duc, T. Omland, A.B. Storrow, W.T. Abraham, A.H. Wu, P. Clopton, P.G. Steg, A. Westheim, C.W. Knudsen, A. Perez, R. Kazanegra, H.C. Herrmann, and P.A. McCullough. 2002. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347: 161-167.
137. Marcus, L.S., D. Hart, M. Packer, M. Yushak, N. Medina, R.S. Danziger, D.F. Heitjan, and S.D. Katz. 1996. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebocontrolled, randomized crossover trial. Circulation 94: 3184-3189.
138. Masoudi, F.A., E.P. Havranek, G. Smith, R.H. Fish, J.F. Steiner, D.L. Ordin, and H.M. Krumholz. 2003. Gender, age, and heart failure with preserved left ventricular systolic function. J. Am. Coll. Cardiol. 41: 217-223.
139. Masson, S., R. Latini, I.S. Anand, T. Vago, L. Angelici, S. Barlera, E.D. Missov, A. Clerico, G. Tognoni, and J.N. Cohn. 2006. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin. Chem. 52: 1528-1538.
140. Masson, S., R. Latini, E. Carbonieri, L. Moretti, M.G. Rossi, S. Ciricugno, V. Milani, R. Marchioli, J. Struck, A. Bergmann, A.P. Maggioni, G. Tognoni, and L. Tavazzi. 2010. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur. J. Heart Fail. 12: 338-347.
141. McCord, J., B.J. Mundy, M.P. Hudson, A.S. Maisel, J.E. Hollander, W.T. Abraham, P.G. Steg, T. Omland, C.W. Knudsen, K.R. Sandberg, and P.A. McCullough. 2004. Relationship between obesity and B-type natriuretic peptide levels. Arch. Intern. Med. 164: 2247-2252.
142. McCullough, P.A., R.M. Nowak, J. McCord, J.E. Hollander, H.C. Herrmann, P.G. Steg, P. Duc, A. Westheim, T. Omland, C.W. Knudsen, A.B. Storrow, W.T. Abraham, S. Lamba, A.H. Wu, A. Perez, P. Clopton, P. Krishnaswamy, R. Kazanegra and A.S. Maisel. 2002a. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106: 416-422.
143. McCullough, P.A., E.F. Philbin, J.A. Spertus, S. Kaatz, K.R. Sandberg, and W.D. Weaver. 2002b. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J. Am. Coll. Cardiol. 39: 60-69.
144. McEntegart, M.B., B. Awede, M.C. Petrie, N. Sattar, F.G. Dunn, N.G. MacFarlane, and J.J. McMurray. 2007. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur. Heart J. 28: 829-835.
145. McMurray, J., M. Chopra, I. Abdullah, W.E. Smith, and H.J. Dargie. 1993. Evidence of oxidative stress in chronic heart failure in humans. Eur. Heart J. 14: 1493-1498.
146. McMurray, J.J., M.C. Petrie, D.R. Murdoch, and A.P. Davie. 1998. Clinical epidemiology of heart failure: public and private health burden. Eur. Heart J. 19 Suppl P: P9-16.
147. McMurray, J.J., S. Adamopoulos, S.D. Anker, A. Auricchio, M. Bohm, K. Dickstein, V. Falk, G. Filippatos, C. Fonseca, M.A. Gomez-Sanchez, T. Jaarsma, L. Kober, G.Y. Lip, A.P. Maggioni, A. Parkhomenko, B.M. Pieske, B.A. Popescu, P.K. Ronnevik, F.H. Rutten, J. Schwitter, P. Seferovic, J. Stepinska, P.T. Trindade, A.A. Voors, F. Zannad, A. Zeiher, J.J. Bax, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, Z. Reiner, U. Sechtem, P.A. Sirnes, M. Tendera, A. Torbicki, A. Vahanian, S. Windecker, L.A. Bonet, P. Avraamides, H.A. Ben Lamin, M. Brignole, A. Coca, P. Cowburn, H. Dargie, P. Elliott, F.A. Flachskampf, G.F. Guida, S. Hardman, B. Iung, B. Merkely, C. Mueller, J.N. Nanas, O.W. Nielsen, S. Orn, J.T. Parissis, and P. Ponikowski. 2012. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 14: 803-869.
148. McNamara, D.M., R. Holubkov, K. Janosko, A. Palmer, J.J. Wang, G.A. MacGowan, S. Murali, W.D. Rosenblum, B. London and A.M. Feldman. 2001. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 103: 1644-1648.
149. Miller, W.L., J.C. Burnett, Jr., K.A. Hartman, D.O. Hodge, I. Giuliani, F. Minard, C. Larue, and A.S. Jaffe. 2009. Role for precursor Pro-B type natriuretic peptide in assessing response to therapy and prognosis in patients with decompensated heart failure treated with nesiritide. Clin. Chim. Acta. 406: 119-123.
150. Mizuno, Y., M. Yoshimura, H. Yasue, T. Sakamoto, H. Ogawa, K. Kugiyama, E. Harada, M. Nakayama, S. Nakamura, T. Ito, Y. Shimasaki, Y. Saito, and K. Nakao. 2001. Aldosterone production is activated in failing ventricle in humans. Circulation 103: 72-77.
151. Moraes, D.L., W.S. Colucci, and M.M. Givertz. 2000. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 102: 1718-1723.
152. Morrow, D.A. and J.A. de Lemos. 2007. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115: 949-952.
153. Mosterd, A., J.W. Deckers, A.W. Hoes, A. Nederpel, A. Smeets, D.T. Linker, and D.E. Grobbee. 1997. Classification of heart failure in population based research: an assessment of six heart failure scores. Eur. J. Epidemiol. 13: 491-502.
154. Murray, D.R. and G.L. Freeman. 2003. Proinflammatory cytokines: predictors of a failing heart? Circulation 107: 1460-1462.
155. Nakamura, K., K. Fushimi, H. Kouchi, K. Mihara, M. Miyazaki, T. Ohe, and M. Namba. 1998. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 98: 794-799.
156. Nakamura, K., K.F. Kusano, H. Matsubara, Y. Nakamura, A. Miura, N. Nishii, K. Banba, S. Nagase, K. Miyaji, H. Morita, H. Saito, T. Emori, and T. Ohe. 2005. Relationship between oxidative stress and systolic dysfunction in patients with hypertrophic cardiomyopathy. J. Card. Fail. 11: 117-123.
157. Nakayama, H., X. Chen, C.P. Baines, R. Klevitsky, X. Zhang, H. Zhang, N. Jaleel, B.H. Chua, T.E. Hewett, J. Robbins, S.R. Houser, and J.D. Molkentin. 2007. Ca2+- and mitochondrialdependent cardiomyocyte necrosis as a primary mediator of heart failure. J. Clin. Invest. 117: 2431-2444.
158. National Heart Lung and Blood Institute: NIH Bethesda MD. 1996. Morbidity and Mortality Chartbook on Cardiocascular, Lung and blood Diseas.
159. Newton, G.E. and J.D. Parker. 1996. Acute effects of beta 1-selective and nonselective betaadrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation 94: 353-358.
160. Nickolas, T.L., J. Barasch, and P. Devarajan. 2008a. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol. Hypertens. 17: 127-132.
161. Nickolas, T.L., M.J. O’Rourke, J. Yang, M.E. Sise, P.A. Canetta, N. Barasch, C. Buchen, F. Khan, K. Mori, J. Giglio, P. Devarajan, and J. Barasch. 2008b. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann. Intern. Med. 148: 810-819.
162. Nilsson, J. 2005. CRP-marker or maker of cardiovascular disease? Arterioscler. Thromb. Vasc. Biol. 25: 1527-1528.
163. Nohria, A., L.M. Mielniczuk, and L.W. Stevenson. 2005. Evaluation and monitoring of patients with acute heart failure syndromes. Am. J. Cardiol. 96: 32G-40G.
164. Noma, T., A. Lemaire, S.V. Naga Prasad, L. Barki-Harrington, D.G. Tilley, J. Chen, P. Le Corvoisier, J.D. Violin, H. Wei, R.J. Lefkowitz, and H.A. Rockman. 2007. Beta-arrestinmediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Invest. 117: 2445-2458.
165. Nozawa, T., A. Igawa, N. Yoshida, M. Maeda, M. Inoue, Y. Yamamura, H. Asanoi, and H. Inoue. 1998. Dual-tracer assessment of coupling between cardiac sympathetic neuronal function and downregulation of beta-receptors during development of hypertensive heart failure of rats. Circulation 97: 2359-2367.
166. Okuyama, M., S. Yamaguchi, N. Nozaki, M. Yamaoka, M. Shirakabe, and H. Tomoike. 1997. Serum levels of soluble form of Fas molecule in patients with congestive heart failure. Am. J. Cardiol. 79: 1698-1701.
167. Omland, T., M.H. Drazner, T. Ueland, M. Abedin, S.A. Murphy, P. Aukrust, and J.A. de Lemos. 2007. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 49: 1392-1398.
168. Palladini, G., C. Campana, C. Klersy, A. Balduini, G. Vadacca, V. Perfetti, S. Perlini, L. Obici, E. Ascari, G.M. d’Eril, R. Moratti, and G. Merlini. 2003. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107: 2440-2445.
169. Peacock, W.F.t., T. De Marco, G.C. Fonarow, D. Diercks, J. Wynne, F.S. Apple, and A.H. Wu. 2008. Cardiac troponin and outcome in acute heart failure. N. Engl. J. Med. 358: 2117-2126.
170. Pearson, T.A., G.A. Mensah, R.W. Alexander, J.L. Anderson, R.O. Cannon, 3rd, M. Criqui, Y.Y. Fadl, S.P. Fortmann, Y. Hong, G.L. Myers, N. Rifai, S.C. Smith, Jr., K. Taubert, R.P. Tracy, and F. Vinicor. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499-511.
171. Pfeffer, M.A. and E. Braunwald. 1990. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81: 1161-1172.
172. Pieroni, M., A. Corti, B. Tota, F. Curnis, T. Angelone, B. Colombo, M.C. Cerra, F. Bellocci, F. Crea, and A. Maseri. 2007. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur. Heart J. 28: 1117-1127.
173. Pinsky, D.J., B. Cai, X. Yang, C. Rodriguez, R.R. Sciacca, and P.J. Cannon. 1995. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. J. Clin. Invest. 95: 677-685.
174. Polidori, M.C., D. Pratico, K. Savino, J. Rokach, W. Stahl, and P. Mecocci. 2004. Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. J. Card. Fail. 10: 334-338.
175. Poutanen, T., T. Tikanoja, P. Riikonen, A. Silvast, and M. Perkkio. 2003. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J. Clin. Oncol. 21: 2349-2356.
176. Querejeta, R., N. Varo, B. Lopez, M. Larman, E. Artinano, J.C. Etayo, J.L. Martinez Ubago, M. Gutierrez-Stampa, J.I. Emparanza, M.J. Gil, I. Monreal, J.P. Mindan, and J. Diez. 2000. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 101: 1729-1735.
177. Rauchhaus, M., W. Doehner, D.P. Francis, C. Davos, M. Kemp, C. Liebenthal, J. Niebauer, J. Hooper, H.D. Volk, A.J. Coats, and S.D. Anker. 2000. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102: 3060-3067.
178. Rehman, S.U., T. Mueller, and J.L. Januzzi, Jr. 2008. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol. 52: 1458-1465.
179. Richards, A.M., R. Doughty, M.G. Nicholls, S. Macmahon, H. Ikram, N. Sharpe, E.A. Espiner, C. Frampton, and T.G. Yandle. 1999. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 99: 786-792.
180. Roach, D.R., A.G. Bean, C. Demangel, M.P. France, H. Briscoe, and W.J. Britton. 2002. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol. 168: 4620-4627.
181. Roberts, R., K.S. Gowda, P.A. Ludbrook, and B.E. Sobel. 1975. Specificity of elevated serum MB creatine phosphokinase activity in the diagnosis of acute myocardial infarction. Am. J. Cardiol. 36: 433-437.
182. Roger, V.L., S.A. Weston, M.M. Redfield, J.P. Hellermann-Homan, J. Killian, B.P. Yawn, and S.J. Jacobsen. 2004. Trends in heart failure incidence and survival in a community-based population. JAMA 292: 344-350.
183. Roger, V.L. 2010. The heart failure epidemic. Int. J. Environ. Res. Public Health 7: 1807-1830.
184. Ronco, C., M. Haapio, A.A. House, N. Anavekar, and R. Bellomo. 2008. Cardiorenal syndrome. J. Am. Coll. Cardiol. 52: 1527-1539.
185. Saenger, A.K. and A.S. Jaffe. 2008. Requiem for a heavyweight: the demise of creatine kinase-MB. Circulation 118: 2200-2206.
186. Sam, F., D.L. Kerstetter, D.R. Pimental, S. Mulukutla, A. Tabaee, M.R. Bristow, W.S. Colucci, and D.B. Sawyer. 2005. Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. J. Card. Fail. 11: 473-480.
187. Sarraf, M., A. Masoumi, and R.W. Schrier. 2009. Cardiorenal syndrome in acute decompensated heart failure. Clin. J. Am. Soc. Nephrol. 4: 2013-2026.
188. Schiffrin, E.L., M.L. Lipman, and J.F. Mann. 2007. Chronic kidney disease: effects on the cardiovascular system. Circulation 116: 85-97.
189. Schrier, R.W. 2006. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am. J. Med. 119: S47-53.
190. Scirica, B.M. and D.A. Morrow. 2006. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 113: 2128-2134; discussion 2151.
191. Seta, Y., K. Shan, B. Bozkurt, H. Oral, and D.L. Mann. 1996. Basic mechanisms in heart failure: the cytokine hypothesis. J. Card. Fail. 2: 243-249.
192. Shah, R.V. and J.L. Januzzi, Jr. 2010. ST2: a novel remodeling biomarker in acute and chronic heart failure. Curr. Heart Fail. Rep. 7: 9-14.
193. Shimpo, M., D.A. Morrow, E.O. Weinberg, M.S. Sabatine, S.A. Murphy, E.M. Antman, and R.T. Lee. 2004. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109: 2186-2190.
194. Sigurdsson, A., O. Amtorp, T. Gundersen, B. Nilsson, J. Remes, and K. Swedberg. 1994. Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group. Br Heart J 72: 422-427.
195. Silvestre, J.S., C. Heymes, A. Oubenaissa, V. Robert, B. Aupetit-Faisant, A. Carayon, B. Swynghedauw, and C. Delcayre. 1999. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 99: 2694-2701.
196. Sliwa, K., A. Woodiwiss, V.N. Kone, G. Candy, D. Badenhorst, G. Norton, C. Zambakides, F. Peters, and R. Essop. 2004. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation 109: 750-755.
197. Somaratne, J.B., C. Berry, J.J. McMurray, K.K. Poppe, R.N. Doughty and G.A. Whalley. 2009. The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis. Eur. J. Heart Fail. 11: 855-862.
198. Stanek, B., B. Frey, M. Hulsmann, R. Berger, B. Sturm, J. Strametz-Juranek, J. Bergler-Klein, P. Moser, A. Bojic, E. Hartter, and R. Pacher. 2001. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J. Am. Coll. Cardiol. 38: 436-442.
199. Sugiura, T., H. Takase, T. Toriyama, T. Goto, R. Ueda and Y. Dohi. 2005. Circulating levels of myocardial proteins predict future deterioration of congestive heart failure. J. Card. Fail. 11: 504-509.
200. Suzuki, T., D. Hayashi, T. Yamazaki, T. Mizuno, Y. Kanda, I. Komuro, M. Kurabayashi, K. Yamaoki, K. Mitani, H. Hirai, R. Nagai, and Y. Yazaki. 1998. Elevated B-type natriuretic peptide levels after anthracycline administration. Am. Heart J. 136: 362-363.
201. Taglieri, N., W. Koenig, and J.C. Kaski. 2009. Cystatin C and cardiovascular risk. Clin. Chem. 55: 1932-1943.
202. Tamura, N., Y. Ogawa, H. Chusho, K. Nakamura, K. Nakao, M. Suda, M. Kasahara, R. Hashimoto, G. Katsuura, M. Mukoyama, H. Itoh, Y. Saito, I. Tanaka, H. Otani, and M. Katsuki. 2000. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc. Natl. Acad. Sci. U S A 97: 4239-4244.
203. Tang, W.H., J.P. Girod, M.J. Lee, R.C. Starling, J.B. Young, F. Van Lente, and G.S. Francis. 2003. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 108: 2964-2966.
204. Tang, W.H., M.L. Brennan, K. Philip, W. Tong, S. Mann, F. Van Lente, and S.L. Hazen. 2006. Plasma myeloperoxidase levels in patients with chronic heart failure. Am. J. Cardiol. 98: 796-799.
205. Tang, W.H., G.S. Francis, D.A. Morrow, L.K. Newby, C.P. Cannon, R.L. Jesse, A.B. Storrow, R.H. Christenson, F.S. Apple, J. Ravkilde, and A.H. Wu. 2007. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 116: e99-109.
206. Teerlink, J.R. 2005. Endothelins: pathophysiology and treatment implications in chronic heart failure. Curr. Heart Fail. Rep. 2: 191-197.
207. The SOLVD Investigators. 1991. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325: 293-302.
208. Tjeerdsma, G., R.A. de Boer, F. Boomsma, M.P. van den Berg, Y.M. Pinto, and D.J. van Veldhuisen. 2002. Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure. Int. J. Cardiol. 86: 143-9; discussion 149-152.
209. Topol, E.J., T.A. Traill, and N.J. Fortuin. 1985. Hypertensive hypertrophic cardiomyopathy of the elderly. N. Engl. J. Med. 312: 277-283.
210. Torre-Amione, G., S. Kapadia, C. Benedict, H. Oral, J.B. Young, and D.L. Mann. 1996a. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. 27: 1201-1206.
211. Torre-Amione, G., S. Kapadia, J. Lee, J.B. Durand, R.D. Bies, J.B. Young, and D.L. Mann. 1996b. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93: 704-711.
212. Trof, R.J., F. Di Maggio, J. Leemreis, and A.B. Groeneveld. 2006. Biomarkers of acute renal injury and renal failure. Shock 26: 245-253.
213. Tsutamoto, T., A. Wada, K. Maeda, T. Hisanaga, N. Mabuchi, M. Hayashi, M. Ohnishi, M. Sawaki, M. Fujii, H. Horie, Y. Sugimoto, and M. Kinoshita. 1999. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur. Heart J. 20: 1799-1807.
214. Ueland, T., R. Jemtland, K. Godang, J. Kjekshus, A. Hognestad, T. Omland, I.B. Squire, L. Gullestad, J. Bollerslev, K. Dickstein, and P. Aukrust. 2004. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J. Am. Coll. Cardiol. 44: 1970-1976.
215. Ungvari, Z., S.A. Gupte, F.A. Recchia, S. Batkai, and P. Pacher. 2005. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr. Vasc. Pharmacol. 3: 221-229.
216. Vaidya, V.S., V. Ramirez, T. Ichimura, N.A. Bobadilla, and J.V. Bonventre. 2006. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J. Physiol. Renal Physiol 290: F517-529.
217. Valgimigli, M., E. Merli, P. Malagutti, O. Soukhomovskaia, G. Cicchitelli, A. Antelli, D. Canistro, G. Francolini, G. Macri, F. Mastrorilli, M. Paolini, and R. Ferrari. 2004. Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction. J. Am. Coll. Cardiol. 43: 2000-2008.
218. van Kimmenade, R.R., J.L. Januzzi, Jr., P.T. Ellinor, U.C. Sharma, J.A. Bakker, A.F. Low, A. Martinez, H.J. Crijns, C.A. MacRae, P.P. Menheere, and Y.M. Pinto. 2006. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J. Am. Coll. Cardiol. 48: 1217-1224.
219. Vasan, R.S., L.M. Sullivan, R. Roubenoff, C.A. Dinarello, T. Harris, E.J. Benjamin, D.B. Sawyer, D. Levy, P.W. Wilson, and R.B. D’Agostino. 2003. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107: 1486-1491.
220. Vatner, D.E., K. Asai, M. Iwase, Y. Ishikawa, R.P. Shannon, C.J. Homcy, and S.F. Vatner. 1999. Beta-adrenergic receptor-G protein-adenylyl cyclase signal transduction in the failing heart. Am. J. Cardiol. 83: 80H-85H.
221. Venugopal, S.K., S. Devaraj, and I. Jialal. 2005. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr. Opin. Nephrol. Hypertens. 14: 33-37.
222. Vickery, S., C.P. Price, R.I. John, N.A. Abbas, M.C. Webb, M.E. Kempson and E.J. Lamb. 2005. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am. J. Kidney Dis. 46: 610-620.
223. Wallace, T.W., S.M. Abdullah, M.H. Drazner, S.R. Das, A. Khera, D.K. McGuire, F. Wians, M.S. Sabatine, D.A. Morrow, and J.A. de Lemos. 2006. Prevalence and determinants of troponin T elevation in the general population. Circulation 113: 1958-1965.
224. Weinberg, E.O., M. Shimpo, G.W. De Keulenaer, C. MacGillivray, S. Tominaga, S.D. Solomon, J.L. Rouleau, and R.T. Lee. 2002. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes, and myocardial infarction. Circulation 106: 2961-2966.
225. Weinberg, E.O., M. Shimpo, S. Hurwitz, S. Tominaga, J.L. Rouleau, and R.T. Lee. 2003. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107: 721-726.
226. Wijeysundera, H.C., M.S. Hansen, E. Stanton, A.S. Cropp, C. Hall, N.S. Dhalla, J. Ghali, and J.L. Rouleau. 2003. Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. Am. Heart J. 146: 291-297.
227. Wilkins, M.R., R.J. Unwin, and A.J. Kenny. 1993. Endopeptidase-24.11 and its inhibitors: potential therapeutic agents for edematous disorders and hypertension. Kidney Int. 43: 273-285.
228. Wollert, K.C. and H. Drexler. 2001. The role of interleukin-6 in the failing heart. Heart Fail. Rev. 6: 95-103.
229. Wollert, K.C., T. Kempf, B. Lagerqvist, B. Lindahl, S. Olofsson, T. Allhoff, T. Peter, A. Siegbahn, P. Venge, H. Drexler, and L. Wallentin. 2007. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation 116: 1540-1548.
230. Wong, N.L., M. Sonntag, and J.K. Tsui. 2003. Attenuation of renal vasopressin V2 receptor upregulation by bosentan, an ETA/ETB receptor antagonist. Metabolism 52: 1141-1146.
231. Wong, S.C., M. Fukuchi, P. Melnyk, I. Rodger, and A. Giaid. 1998. Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. Circulation 98: 100-103.
232. Zacho, J., A. Tybjaerg-Hansen, J.S. Jensen, P. Grande, H. Sillesen, and B.G. Nordestgaard. 2008. Genetically elevated C-reactive protein and ischemic vascular disease. N. Engl. J. Med. 359: 1897-1908.
233. Zannad, F., F. Alla, B. Dousset, A. Perez, and B. Pitt. 2000. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102: 2700-2706.
234. Zile, M.R. and D.L. Brutsaert. 2002. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 105: 1387-1393.
235. Zimmet, J.M. and J.M. Hare. 2006. Nitroso-redox interactions in the cardiovascular system. Circulation 114: 1531-1544.